Turalio Disease Interactions
There are 2 disease interactions with Turalio (pexidartinib).
Pexidartinib (applies to Turalio) hepatic dysfunction
Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease, Bile Acid Synthesis Disorders, Biliary Obstruction
Pexidartinib can cause serious and potentially fatal liver injury. No dose adjustment of pexidartinib is needed for patients with mild hepatic impairment. Caution should be exercised when using this agent in patients with moderate to severe hepatic impairment as the recommended dose has not been established in these patients. Avoid this drug in patients with preexisting increased serum transaminases; total bilirubin or direct bilirubin (greater than ULN); or active liver or biliary tract disease, including increased alkaline phosphatase. It is recommended to monitor liver tests before initiation of treatment and at specified intervals during treatment. Withhold and reduce the dose or permanently discontinue pexidartinib based on the severity of hepatotoxicity.
Pexidartinib (applies to Turalio) renal Impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
Dose modification of pexidartinib is needed for patients with renal impairment. It is recommended to reduce the dose when administering pexidartinib to patients with mild to severe renal impairment (CrCl 15 to 89 mL/min, estimated by Cockcroft-Gault using actual body weight). The recommended dosage is 200 mg in the morning and 400 mg in the evening.
Turalio drug interactions
There are 614 drug interactions with Turalio (pexidartinib).
Turalio alcohol/food interactions
There are 2 alcohol/food interactions with Turalio (pexidartinib).
More about Turalio (pexidartinib)
- Turalio consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.